BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts' - 2'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- 3NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 4Ringleader of suspected human trafficking network arrested in Ethiopia
- 5French rapper Gims placed under investigation for 'aggravated money laundering'
- New subclade K flu strain raises concerns: What families should know
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Is Iran using cryptocurrencies to circumvent sanctions?
- Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- Overlooked infertility care should be part of national health services, says WHO
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
